Skip to content

Trial · Interventional

CompletedPhase 1Results postedRegistry data

Safety, Tolerability, and Pharmacokinetic Study of Methylene Blue Following a 1 mg/kg Intravenous Dose in Healthy Adults

NCTNCT02478281 (opens ClinicalTrials.gov in a new tab)Other id1MBL12002
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase 1
Enrollment
12 participants (actual)
Sponsor
American Regent, Inc. · Industry
Design
Allocation not applicable · Open label (no masking)
Countries
Not stated
Start
Oct 2012
Primary completion
Oct 2012
Completion
Mar 2013
First posted
23 Jun 2015 (estimated)
Last update posted
5 Jun 2025
Conditions
Methemoglobinemia · Congenital Methemoglobinemia

Timeline

1 trial · 1 completed · 1 with posted results

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
201220132014
  1. Ph 1

    Safety, Tolerability, and Pharmacokinetic Study of Methylene Blue Following a 1 mg/kg Intravenous Dose in Healthy Adults

    NCT02478281

    Oct 2012 to Mar 2013

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

A Phase 1 trial to assess the single-dose safety, tolerability, and pharmacokinetic (PK) of Methylene Blue Injection, USP 1 mg/kg in healthy adult volunteers.

Interventions

  • Methylene BlueDrug

Arms1

  • Experimental

    Methylene Blue Injection, United States Pharmacopeia (USP)

    Single dose of Methylene Blue Injection, USP at a dose of 1 mg/kg solution per kg given intravenously over a period of approximately 5 minutes.

Primary outcomes11

Outcomes the sponsor listed as primary.

  1. Area Under the Curve (AUC) From Time Zero to the Time of Last Quantifiable Concentration (AUC 0-t)

    Time frame · pre-dose, 0.042, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 16, 36, 48, and 72 hours post-dose

    Registry description

    The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample; AUC 0-t is defined as AUC from time 0 to the last data point

  2. Area Under the Curve From Time Zero Extrapolated to Infinity (AUC 0-∞)

    Time frame · pre-dose, 0.042, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 16, 36, 48, and 72 hours post-dose

    Registry description

    The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. AUC 0-∞ is defined as area under the concentration vs. time curve from zero to infinity.

  3. The Percent of Extrapolated Area Under the Curve (AUC%Extrap)

    Time frame · pre-dose, 0.042, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 16, 36, 48, and 72 hours post-dose

    Registry description

    The AUC%extrap refers to the fraction of the total AUC that is due to the extrapolated AUC

  4. Area Under the Curve Ratio (AUCR)

    Time frame · pre-dose, 0.042, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 16, 36, 48, and 72 hours post-dose

    Registry description

    AUCR refers to the ratio of AUC 0-t to AUC 0-∞.

  5. Total Body Clearance (CL)

    Time frame · pre-dose, 0.042, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 16, 36, 48, and 72 hours post-dose

    Registry description

    CL refers to the Dose/AUC 0-∞

  6. Maximum Measured Plasma Concentration (Cmax)

    Time frame · pre-dose, 0.042, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 16, 36, 48, and 72 hours post-dose

    Registry description

    Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.

  7. Time to Maximum Plasma Concentration (Tmax)

    Time frame · pre-dose, 0.042, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 16, 36, 48, and 72 hours post-dose

    Registry description

    Tmax refers to the time it takes for a drug to reach maximum concentration

  8. Terminal Elimination Half-life (T1/2)

    Time frame · pre-dose, 0.042, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 16, 36, 48, and 72 hours post-dose

    Registry description

    T1/2 refers to the time taken for concentration of a drug to decrease from its maximum concentration to half of Cmax

  9. Terminal Elimination Rate Constant (Lambda Z)

    Time frame · pre-dose, 0.042, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 16, 36, 48, and 72 hours post-dose

    Registry description

    Lambda Z refers to the terminal elimination phase for drug plasma concentration vs. time data

  10. Volume of Distribution (Vz) Based on Terminal Phase

    Time frame · pre-dose, 0.042, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 16, 36, 48, and 72 hours post-dose

    Registry description

    Vz refers to the ratio of amount of drug in a body (dose) to concentration of the drug that is measured in blood, plasma, and un-bound in interstitial fluid.

  11. Mean Residence Time (MRT)

    Time frame · pre-dose, 0.042, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 16, 36, 48, and 72 hours post-dose

    Registry description

    MRT refers to the average amount of time that a drug molecule spends in the body before being removed

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcomeGeometric mean· pre-dose, 0.042, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 16, 36, 48, and 72 hours post-dose

Area Under the Curve (AUC) From Time Zero to the Time of Last Quantifiable Concentration (AUC 0-t)

GroupValue (ng*hr/mL)Spread
Methylene Blue Injection, USP2600.0928.7
Primary outcomeGeometric mean· pre-dose, 0.042, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 16, 36, 48, and 72 hours post-dose

Area Under the Curve From Time Zero Extrapolated to Infinity (AUC 0-∞)

GroupValue (ng*hr/mL)Spread
Methylene Blue Injection, USP2967.0927.9
Primary outcomeGeometric mean· pre-dose, 0.042, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 16, 36, 48, and 72 hours post-dose

The Percent of Extrapolated Area Under the Curve (AUC%Extrap)

GroupValue (Percent of AUC)Spread
Methylene Blue Injection, USP11.7232.9
Primary outcomeGeometric mean· pre-dose, 0.042, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 16, 36, 48, and 72 hours post-dose

Area Under the Curve Ratio (AUCR)

GroupValue (Percent)Spread
Methylene Blue Injection, USP87.634.6
Primary outcomeGeometric mean· pre-dose, 0.042, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 16, 36, 48, and 72 hours post-dose

Total Body Clearance (CL)

GroupValue (L/hour)Spread
Methylene Blue Injection, USP19.0222.5
Primary outcomeGeometric mean· pre-dose, 0.042, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 16, 36, 48, and 72 hours post-dose

Maximum Measured Plasma Concentration (Cmax)

GroupValue (ng/mL)Spread
Methylene Blue Injection, USP457.3441.9
Primary outcomeGeometric mean· pre-dose, 0.042, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 16, 36, 48, and 72 hours post-dose

Time to Maximum Plasma Concentration (Tmax)

GroupValue (Hours)Spread
Methylene Blue Injection, USP0.217126.7
Primary outcomeGeometric mean· pre-dose, 0.042, 0.083, 0.167, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 16, 36, 48, and 72 hours post-dose

Terminal Elimination Half-life (T1/2)

GroupValue (Hours)Spread
Methylene Blue Injection, USP15.90846.3

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
GroupDeathsSerious eventsOther events
Methylene Blue Injection, USPSingle dose of Methylene Blue Injection, USP at a dose of 1 mg/kg solution per kg given intravenously over a period of approximately 5 minutes. Methylene Blue0 / 120 / 1210 / 12

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 60 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Healthy adult male or female volunteers, 18-60 years of age, inclusive. * Weigh at least 52 kg for males and 45 kg for females and within the normal range according to accepted normal values of the Body Mass Index (BMI) chart 18.5-29.9 kg/m² inclusive. * Medically healthy with no clinically significant laboratory profiles, vital signs, or ECG's; as deemed by the PI. * For females of childbearing potential: either be sexually inactive (abstinent) for 14 days prior to the first dose and throughout the study or be using acceptable birth control methods. Female subjects who claim to be sexually inactive, but become sexually active during the course of the study must agree to use a barrier method (e.g. condom, diaphragm)with spermicide from the time of the start of sexual activity through at least 30 days following dosing. In addition, female subjects of childbearing potential will be advised to remain sexually inactive or to keep the same birth control method for at least 30 days following dosing. * Females of non-childbearing potential must have undergone one of the following sterilization procedures at least 6 months prior to Day 1: * Hysteroscopic tubal ligation (with a copy of the confirmation test) and be using a barrier method (condom or diaphragm) and spermicide throughout the study; * Bilateral tubal ligation and be using a barrier method (condom or diaphragm) and spermicide throughout the study; * Hysterectomy; * Bilateral oophorectomy or be postmenopausal with amenorrhea for at least 1 year prior to Day 1 and follicle stimulating hormone (FSH) serum levels ≥ 40 milli-International Units per mL (mIU/mL). Females on hormone replacement therapy may be deemed eligible for participation in the study even if their FSH levels \< 40 mIU/mL, if they are able to provide documentation of FSH levels 40 mIU/mL before initiation of hormone replacement therapy. * Males must use condom with spermicide when engaged in sexual activity and must agree to refrain from sperm donation from check-in through 90 days postdose. * Willing to answer inclusion and exclusion criteria questionnaire at check-in. * Give voluntary written informed consent to participate in the study. * Be able to comply with the protocol and the assessments therein. Exclusion Criteria: * History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease in the opinion of the PI. * History or presence of alcoholism within the past 2 years. * History or presence of drug abuse within the past 2 years. * History or presence of hypersensitivity or idiosyncratic reaction to Methylene Blue. * History or presence of Glucose-6-Phosphate Dehydrogenase (G6PD) dehydrogenase deficiency, retinopathy, blood disorder, myasthenia gravis, psoriasis, epilepsy, clinically significant allergies (except for mild forms of hay fever), or any other clinically significant medical condition, which in the opinion of the PI, might interfere with study participation. * History or laboratory evidence of renal insufficiency. * Any screening laboratory test with clinically significant abnormalities in the opinion of the PI (including cell blood count, creatinine, or liver function tests). * Have used any drug that acts as a serotonin reuptake inhibitor (SRIs) e.g. selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), norepinephrine-dopamine reuptake inhibitors (NDRIs), triptans, or ergot alkaloids within 30 days (or 5 half-lives of the compound, whichever is longer) prior to study drug dosing. * Female subjects who are pregnant or lactating, or female subjects who are likely to become pregnant during the study. * Had positive results for the urine drug/alcohol screen at screening or check-in. * Had positive results at screening for HIV, HBsAg, or hepatitis C virus (HCV). * Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening. * Heart rate is lower than 40 bpm or higher than 99 bpm at screening. * QTc interval is \>430 msec (males) or \>450 msec (females) or deemed clinically abnormal by the PI or use of any drug or agent suspected of causing QT prolongation or torsade de pointes within 14 days (or 5 half- lives of the compound, whichever is longer) prior to study drug dosing. * Have been on a special diet (for whatever reason) within the 28 days prior to study drug dosing, and throughout the study. * Have made a donation of blood or had significant blood loss within 56 days prior to study drug dosing. * Have made a plasma donation within 7 days prior to study drug dosing. * Have received Methylene Blue within 72 hours prior to study drug dosing. * Have participated in another clinical trial within 30 days (or 5 half-lives of the compound, whichever is longer) prior to study drug dosing.

PepBank is a research reference. Talk to a doctor before you use any peptide.